Back to today’s briefing

Story perspectives

Pfizer Halts Weight-Loss Pill Amid Safety Concerns

4/14/2025

46 4

Summary

Story summary

Pfizer has halted the development of danuglipron, an oral weight-loss pill, following a trial participant's potential liver injury, which improved after discontinuation. Despite this setback, Pfizer is determined to pursue other obesity treatments as it vies for a share in the booming $144 billion weight-loss drug market, competing against Eli Lilly and Novo Nordisk.

1 of 1

Story summary

Pfizer has halted the development of danuglipron, an oral weight-loss pill, following a trial participant's potential liver injury, which improved after discontinuation. Despite this setback, Pfizer is determined to pursue other obesity treatments as it vies for a share in the booming $144 billion weight-loss drug market, competing against Eli Lilly and Novo Nordisk.